Dyadic International, Inc. (DYAI)
DYAI Stock Price Chart
Explore Dyadic International, Inc. interactive price chart. Choose custom timeframes to analyze DYAI price movements and trends.
DYAI Company Profile
Discover essential business fundamentals and corporate details for Dyadic International, Inc. (DYAI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Jan 2008
Employees
6.00
Website
https://www.dyadic.comCEO
Mark A. Emalfarb
Description
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.
DYAI Financial Timeline
Browse a chronological timeline of Dyadic International, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.03, while revenue estimate is $1.03m.
Earnings released on 13 May 2026
EPS came in at -$0.05 falling short of the estimated -$0.04 by -25.00%, while revenue for the quarter reached $1.11m , beating expectations by +22.93%.
Earnings released on 25 Mar 2026
EPS came in at -$0.06 falling short of the estimated -$0.03 by -100.00%, while revenue for the quarter reached $564.35k , missing expectations by -57.99%.
Earnings released on 12 Nov 2025
EPS came in at -$0.06 falling short of the estimated -$0.04 by -50.00%, while revenue for the quarter reached $1.16m , missing expectations by -13.30%.
Earnings released on 13 Aug 2025
EPS came in at -$0.06 matching the estimated -$0.06, while revenue for the quarter reached $463.45k , missing expectations by -69.10%.
Earnings released on 14 May 2025
EPS came in at -$0.07 , while revenue for the quarter reached $393.57k .
Earnings released on 26 Mar 2025
EPS came in at -$0.05 falling short of the estimated -$0.04 by -25.00%, while revenue for the quarter reached $817.38k , missing expectations by -48.91%.
Earnings released on 12 Nov 2024
EPS came in at -$0.01 surpassing the estimated -$0.07 by +85.71%, while revenue for the quarter reached $1.96m , beating expectations by +22.34%.
Earnings released on 13 Aug 2024
EPS came in at -$0.07 matching the estimated -$0.07, while revenue for the quarter reached $385.90k , missing expectations by -61.41%.
Earnings released on 14 May 2024
EPS came in at -$0.07 , while revenue for the quarter reached $334.62k .
Earnings released on 28 Mar 2024
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $686.54k , missing expectations by -14.18%.
Earnings released on 8 Nov 2023
EPS came in at -$0.06 matching the estimated -$0.06, while revenue for the quarter reached $397.06k , missing expectations by -50.37%.
Earnings released on 9 Aug 2023
EPS came in at -$0.07 falling short of the estimated -$0.05 by -40.00%, while revenue for the quarter reached $837.16k , missing expectations by -35.60%.
Earnings released on 10 May 2023
EPS came in at -$0.03 , while revenue for the quarter reached $978.05k .
Earnings released on 29 Mar 2023
EPS came in at -$0.07 matching the estimated -$0.07, while revenue for the quarter reached $743.73k , missing expectations by -48.71%.
Earnings released on 10 Nov 2022
EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%, while revenue for the quarter reached $879.60k , missing expectations by -53.71%.
Earnings released on 10 Aug 2022
EPS came in at -$0.12 falling short of the estimated -$0.09 by -33.33%, while revenue for the quarter reached $658.55k , missing expectations by -64.21%.
Earnings released on 12 May 2022
EPS came in at -$0.09 matching the estimated -$0.09, while revenue for the quarter reached $648.43k , missing expectations by -72.56%.
Earnings released on 29 Mar 2022
EPS came in at -$0.15 falling short of the estimated -$0.03 by -500.00%, while revenue for the quarter reached $313.29k , beating expectations by +82.68%.
Earnings released on 10 Nov 2021
EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%, while revenue for the quarter reached $692.93k , missing expectations by -20.63%.
Earnings released on 12 Aug 2021
EPS came in at -$0.14 falling short of the estimated -$0.09 by -55.56%, while revenue for the quarter reached $937.09k , beating expectations by +0.01%.
DYAI Stock Performance
Access detailed DYAI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
